UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

Completed · Phase 2

Conditions studied: Malignant Melanoma

In brief

This is a randomized, open label study to investigate efficacy and safety of UV1 vaccination in combination with nivolumab and ipilimumab as first line treatment of adult patients with histologically confirmed unresectable metastatic melanoma.

Key facts

Study ID

NCT04382664

Run by

Ultimovacs ASA

People needed

156

Starts

2020-05-27

Expected to finish

2024-04-10

Last updated by the study team

2025-01-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female patients at least 18 years of age at the time of signing the ICF.
• Histologically confirmed diagnosis of unresectable stage IIIB D, or unresectable stage IV malignant melanoma.
• Eligible for combination treatment with nivolumab and ipilimumab.
• An ECOG performance status of 0 or 1.
• Adequate organ function as indicated by the following laboratory values:
• Hematological
• Absolute neutrophil count ≥1,500/µL
• Platelet count ≥100 x 103/µL
• Hemoglobin ≥9 g/dL or ≥5.6 mmol/L Renal
• Creatinine ≤1.5 x upper limit of normal (ULN) Hepatic
• Total bilirubin ≤1.5 x ULN or direct bilirubin ≤ ULN for patients with total bilirubin levels >1.5 ULN
• Aspartate aminotransferase/serum glutamic oxaloacetic transaminase and alanine aminotransferase/serum glutamic pyruvic transaminase ≤2.5 x ULN for patients without liver metastasis or ≤5 x ULN for patients with liver metastasis.
• Male patients who are sexually active with a female of childbearing potential must agree to use an adequate method of contraception.
• Women of childbearing potential (WOCBP) must have a negative urine or serum/plasma pregnancy test.
• WOCBP must use adequate contraception.

You may not qualify if…

• Previous non melanoma malignancies unless curatively treated and complete remission was achieved at least 2 years prior to randomization. Patients with prior curatively treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or carcinoma in situ of the breast, or other in situ cancers are allowed irrespective of time passed since curative treatment. Patients with prior completely resected malignant melanoma are also allowed.
• Known brain metastases or leptomeningeal metastases. If a patient experiences neurological symptoms indicative of brain metastases, a brain MRI should be performed.
• Diagnosis of uveal or ocular melanoma.
• Known history or any evidence of active, non-infectious pneumonitis.
• History of New York Heart Association class 3-4 congestive heart failure or history of myocardial infarction within 6 months of starting induction therapy.
• Active infection requiring systemic treatment.
• Diagnosis of immunodeficiency.
• Known history of severe hypersensitivity reactions to nivolumab, ipilimumab, sargramostim, or their excipients.
• Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies).
• History of or active hepatitis B (hepatitis B surface antigen reactive) or active hepatitis C (hepatitis C virus antibody).
• Women who are breastfeeding.
• Prior systemic treatment for unresectable stage IIIB D or unresectable stage IV malignant melanoma.
• Systemic corticosteroid treatment (doses exceeding 10 mg daily of prednisone or equivalent) or any other form of immunosuppressive treatment within 7 days prior to the first dose of induction therapy.
• Receipt of a live vaccine within 30 days prior to start of induction therapy.
• Receipt of any other investigational treatment within 4 weeks of the first dose of induction therapy.
• Any medical, psychological, or social condition that would make it difficult for the patient to participate in the study and comply with the study procedures, restrictions and requirements.

Where it is running

• Mayo Clinic Hospital — Phoenix, Arizona, United States
• Highlands Oncology Group — Fayetteville, Arkansas, United States
• University of California Irvine Health — Orange, California, United States
• California Cancer Associates for Research & Excellence (CCARE — San Marcos, California, United States
• Ridley-Tree Cancer Center — Santa Barbara, California, United States
• Saint John's Health Center - John Wayne Cancer Institute (JWCI) — Santa Monica, California, United States
• University of Colorado Hospital - Anschutz Cancer Pavilion — Aurora, Colorado, United States
• Holy Cross Medical Group — Fort Lauderdale, Florida, United States
• Sylvester Comprehensive Cancer Center — Miami, Florida, United States
• Ocala Oncology Center — Ocala, Florida, United States
• Rush University Medical Center - Rush University Cancer Center — Chicago, Illinois, United States
• NorthShore University Research Institute — Evanston, Illinois, United States
• Oncology Specialists, S.C. — Park Ridge, Illinois, United States
• Norton Cancer Institute — Louisville, Kentucky, United States
• Nebraska Cancer Specialists- Midwest Cancer Center — Papillion, Nebraska, United States
• Icahn School of Medicine at Mount Sinai — New York, New York, United States
• State University of New York (SUNY) Upstate Medical University — New York, New York, United States
• University of Rochester — Rochester, New York, United States
• NorthShore University HealthSystem — Greenville, South Carolina, United States
• Texas Oncology - Baylor Charles A. Sammons Cancer Center — Dallas, Texas, United States
• Antwerp University Hospital — Antwerp, Belgium
• Cliniques Universitaires Saint-Luc — Brussels, Belgium
• Leuven University Hospital — Leuven, Belgium
• GZA Hospital Sint-Augustinus — Wilrijk, Belgium
• Ålesund Hospital- Helse Sunnmore HF — Ålesund, Norway

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.